AdAlta (ASX:1AD) has announced an addition to its AdCella leadership team, with Dr Kevin Lynch appointed as consultant chief medical officer.
AdAlta said Dr Lynch will support the selection of in-licensed cellular immunotherapies and the design and execution of Phase 1 clinical trials by AdCella. These clinical programs remain subject to the completion of financing and licensing arrangements.
AdAlta CEO and managing director Tim Oldham said, "We are delighted that Kevin has agreed to work with AdAlta as we build our clinical pipeline of cellular immunotherapies. Kevin brings deep expertise in clinical development in oncology, cell therapies and China to AdCella.
"This appointment is further demonstration that AdAlta has in place a well-credentialled team primed to deliver our AdCella strategy. We are also appointing a Consultant Chief Medical Officer-AdSolis who will bring decades or respiratory drug development, including in IPF, to AD-214 and our AdSolis subsidiary.”
Dr Lynch is a highly experienced industry physician. His experience spans all stages of clinical development, regulatory and reimbursement approvals and post-registration medical activities. He has contributed to multiple therapies in haematology and oncology at both early- to late-stage therapies, including imatinib, nilotinib, lenalidomide and pomalidomide.
Dr Lynch is a co-founder of PopulusBio srl, a company focused on accelerating the development of therapies for people with debilitating diseases. His previous leadership roles include chief medical officer at Antengene and senior medical and clinical roles at Celgene and Novartis.